Systimmune reported that izalontamab brengitecan (iza‑bren) met both progression‑free survival and overall survival endpoints in a phase III trial in Chinese patients with advanced triple‑negative breast cancer (TNBC). The readout validates the licensee Bristol Myers Squibb’s investment and supports potential regulatory filings in the region. The trial results provide evidence of clinical benefit in a difficult‑to‑treat population and could position iza‑bren as a new option for advanced TNBC if regulators accept the data package. Sponsors and partners will now evaluate global development strategies, potential label claims, and steps needed to support broader registration outside China. Investors and oncology drug developers will watch for detailed safety data and subgroup analyses to assess how the agent might integrate with existing treatment paradigms.